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Abstract
The metabolic syndrome (MetS) is defined as the concurrence of obesity-associated cardiovascular 
risk factors including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, 
decreased HDL cholesterol, and/or hypertension. Earlier conceptualizations of the MetS focused 
on insulin resistance as a core feature, and it is clearly coincident with the above list of features. 
Each component of the MetS is an independent risk factor for cardiovascular disease and the 
combination of these risk factors elevates rates and severity of cardiovascular disease, related to a 
spectrum of cardiovascular conditions including microvascular dysfunction, coronary 
atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure. 
While advances in understanding the etiology and consequences of this complex disorder have 
been made, the underlying pathophysiologic mechanisms remain incompletely understood, and it 
is unclear how these concurrent risk factors conspire to produce the variety of obesity-associated 
adverse cardiovascular diseases. In this review we highlight current knowledge regarding the 
pathophysiologic consequences of obesity and the MetS on cardiovascular function and disease, 
including considerations of potential physiologic and molecular mechanisms that may contribute 
to these adverse outcomes.
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INTRODUCTION
The association between visceral obesity, hypertension, and atherosclerosis was recognized 
as early as 1765 by Joannes Baptista Morgagni in his seminal work entitled ‘De sedibus et 
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causis morborum per anatomen indagata’.(1) Later studies by Hitzenberger, Richter-Quitner, 
and Kylin in the early 1920’s further documented the co-incident relationships between 
metabolic abnormalities such as hyperglycemia, hypertension, and other maladies such as 
hyperuricaemia.(2) These pioneering efforts laid the groundwork for what is now commonly 
referred to as the “Metabolic Syndrome” (MetS), a clustering of inter-related and co-incident 
risk factors which include abdominal obesity, impaired glucose tolerance, 
hypertriglyceridemia, diminished high density lipoprotein (HDL) cholesterol, and/or 
hypertension.(3) The original conceptualization of this syndrome focused on a central role of 
insulin resistance,(3) and this is clearly a concurrent and associated feature. More recently 
the focus has been on the MetS as an epidemiologic tool related to cardiovascular disease 
risk, and therefore traditional cardiovascular disease risk factors have been adopted as the 
defining features. Although the precise definition of what clinically constitutes the MetS has 
generated considerable debate, it is well accepted that these co-morbidities represent a 
pathological state that substantially augments risk for the development of type 2 diabetes 
mellitus and atherosclerotic cardiovascular disease.(4)
As of 2014, the Centers for Disease Control and Prevention estimates that ~70% of adults in 
the United States are overweight or obese, with ~40% of these individuals considered obese 
(defined as body mass index (BMI) ≥30 kg/m2). The National Health and Nutritional 
Examination Survey (NHANES) estimates that ~30% of overweight and ~60% of obese men 
and women meet the criteria for a diagnosis of MetS;(5) in other words, a majority of obese 
people carry the concurrent risk features that identify them as carrying augmented risk of 
cardiovascular disease. Therefore, in parallel with the obesity epidemic, the MetS is a 
growing epidemic, affecting ~20% of adults in the Western world.(6) Each component of the 
MetS is an independent risk factor for cardiovascular disease,(4, 6) together producing a 
wide spectrum of vascular and cardiac diseases.(7-13) While some advances in 
understanding the etiology and consequences of this complex disorder have been made, the 
underlying mechanisms that translate these obesity-associated risk factors into the full 
spectrum of observed cardiovascular pathologies remain insufficiently explained. The 
purpose of this review is to highlight current knowledge regarding the pathophysiologic 
consequences of obesity and the MetS and to outline recent advances in potential 
mechanisms that may contribute to these adverse cardiovascular outcomes. The literature 
linking type 2 diabetes with cardiovascular outcomes will not be reviewed in detail, because 
type 2 diabetes exerts effects on cardiovascular disease distinct from those of the underlying 
obesity and MetS and this would detract from our focus on obesity/MetS. Previous reviews 
by Abel et al.,(14) Poirier et al.,(15) Jiamspripong et al.,(16) Mottillo et al.,(17) Bastien et 
al.,(18) and Grundy and colleagues.(4, 11, 19) have summarized current epidemiology or 
evaluated specific cardiac conditions in the connection between obesity/MetS and 
cardiovascular disease. Here we focus on physiologic and pathophysiologic aspects of 
obesity- and MetS-associated changes in hemodynamics, microvascular dysfunction, 
myocardial metabolism, atherosclerosis and calcification, and infarction and heart failure.
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HEMODYNAMIC AND CARDIAC EFFECTS OF OBESITY AND THE 
METABOLIC SYNDROME
The observed association of obesity with hypertension prompted a body of work exploring 
causes and effects of obesity on the heart. Chronic increases in body weight and adiposity 
can lead to significant neuro-hormonal changes and adaptations in the cardiovascular 
system.(18, 20) These alterations include activation of the activation of the renin-
angiotensin-aldosterone system,(21, 22) altered levels of adipocytokines,(23-27) and pro-
inflammatory cytokines(28, 29), and activation of the sympathetic nervous system.(30-33) 
Sympathetic nervous system activation can contribute to commonly described increases in 
heart rate, renal sodium retention, circulating blood volume, ventricular end-diastolic 
volume (pre-load), cardiac output, and/or blood pressure.(18, 30, 34) More generally, over 
activation of the sympathetic nervous system can concurrently drive abnormalities of 
vascular and cardiac function (e.g. vasoconstriction, tachycardia) and abnormalities of 
metabolic balance (e.g. excess lipolysis driving fatty acid levels, cathechol-induced 
peripheral and hepatic insulin resistance) (33). The degree to which these changes result 
directly from adrenergic receptor activation versus secondary alterations in adipokines, 
cytokines, and renal salt and water retention remains an active area of investigation.
Although insulin resistance has been dropped from the clinical definition of the MetS, the 
fact remains that underlying insulin resistance contributes to many of the features of the 
MetS (dysglycemia, elevated fatty acid levels, hyperinsulinemia and potentially a 
contribution of hyperinsulinemia to sympathetic system activation, among others)(35, 36). 
The epidemiologic literature consistently demonstrates associations of hyperinsulinemia 
with obesity-related heart disease (37). Studies of the metabolic physiology of insulin 
resistance have led to a deeper understanding of the interplay of fuel selection, with excess 
fatty acids contributing in part to cellular resistance to glucose metabolism but also with 
impairment in insulin receptor and post-receptor signaling events and abnormalities in 
mitochondrial number and function all contributing to the overall phenomenon (38-40). The 
contributions of these factors to abnormalities in myocardial metabolism are reviewed 
below.
Obesity-associated changes in cardiac function have been described as the ‘cardiomyopathy 
of obesity’. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) demonstrate a 
direct association between left ventricular end-diastolic volume and body mass index in men 
and in women.(41) This large population based study also found that left ventricular mass 
increased to a greater extent than ventricular volume in obesity.(23, 41) Although early 
studies into the ‘cardiomyopathy of obesity’ suggested that obesity resulted in volume 
overload and eccentric cardiac hypertrophy,(42, 43) more recent findings have established 
that the majority of obese subjects develop concentric left ventricular hypertrophy as well as 
mild (subclinical) diastolic and/or systolic dysfunction, with normal or elevated left 
ventricular ejection fraction.(41, 44-48) This can be associated with poor outcomes 
following cardiac intervention procedures (49). More sensitive measures of contractile 
function such as left ventricular fractional shortening, systolic velocity, and myocardial 
strain (circumferential and longitudinal) have been shown to be impaired in the setting of 
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obesity and/or MetS.(45, 48, 50, 51) Alterations in load-independent measures of 
myocardial contractility (e.g. end-systolic pressure volume relationship) have also been 
reported in animal models of obesity/MetS(52-54) and in obese humans with essential 
hypertension.(55) Importantly, cardiac functional responses to physiologic perturbations 
(e.g. exercise),(56-58) pathologic conditions (e.g. myocardial ischemia)(59-61), or 
pharmacologic stimuli (e.g. catecholamines, glucagon-like-peptide-1 mimetics)(52, 62, 63) 
are also known to be significantly influenced by an obese/MetS phenotype.
The molecular mechanisms underlying this cardiac and hemodynamic phenotype are 
complex and incompletely characterized. Investigators in this field have identified relevant 
and important molecular pathways linking obesity to cardiac dysfunction. In particular, 
alterations in myocardial Ca2+ handling via changes in the functional expression of 
SERCA2A and ryanodine (RyR2) receptors(52, 57, 64) have been of interest, including a 
recent comprehensive paper demonstrating concurrent effects of RyR2 abnormalities to 
induced myocellular and β-cell dysfunction (65), affecting subcellular structures in addition 
to producing abnormalities in intracellular Ca2+ handling (66). This shared dependence of 
the myocardium and β-cell highlights the need for further studies in to the mechanisms 
underlying the dysfunctional regulation of Ca2+ in obesity/MetS. Also of note is a growing 
interest on modifications in the regulation of myocardial titin (which influences the passive 
and restoring force of the cardiac sarcomere and can contribute to hypertrophic signaling) as 
a potential target or mediator of obesity-associated cardiac dysfunction.(52, 67-71) There is 
of course the added possibility that progressive vascular disease further influences these 
changes through mechanisms specific to the atherosclerotic process, or relating to 
microvascular dysfunction, independent of the obese state.(7, 9, 72) These examples 
highlight the opportunities to better understand the pathophysiologic manifestations of 
obesity/MetS by exploring key shared cellular mechanisms.
MICROVASCULAR DYSFUNCTION IN OBESITY AND THE METABOLIC 
SYNDROME
In all vascular beds, the microcirculation is the primary site of blood flow regulation, 
through regulation of resistance to flow at the level of the microvasculature. Microvascular 
resistance is simultaneously modulated by a variety of intrinsic (myogenic) and extrinsic 
(endothelial, neural, hormonal, metabolic) mechanisms which collectively dictate overall 
tissue perfusion.(73) There is a strong body of evidence demonstrating that control of 
microvascular tone and microvascular density are significantly impacted by obesity status, 
and that the MetS is similarly associated with physiologically important alterations in the 
regulation of arteriolar resistance. For example, changes in microvascular structure and 
function in obesity/MetS have been shown to result in an overall imbalance between tissue 
oxygen delivery and metabolism in many vascular beds, including heart,(7, 9, 74, 75) 
kidney,(76) brain,(77) and skeletal muscle.(78, 79)
In the coronary circulation, microvascular dysfunction has been demonstrated as reductions 
in coronary vasodilator responsiveness to a variety of pharmacologic agonists.(75, 80-82) 
Importantly, diminished coronary flow reserve is a powerful predictor of major adverse 
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cardiovascular events.(72) Furthermore, the MetS significantly impairs the balance between 
coronary blood flow and myocardial metabolism in response to exercise (local metabolic 
vasodilation),(83, 84) with alterations in coronary perfusion pressure (pressure-flow 
autoregulation),(85) and in response to cardiac ischemia (reactive hyperemia).(84) 
Importantly, these changes occur prior to any evidence of overt atherosclerotic disease and 
have been associated with diminished diastolic and systolic contractile function in obese/
MetS in humans(47, 86, 87) and in animal models.(20, 57, 88) These findings indicate that 
underlying coronary microvascular dysfunction likely contributes to reductions in cardiac 
contractile function,(45, 47, 48, 51) to concentric ventricular hypertrophy,(41, 44-48, 89) 
and to the significant increases in risk of myocardial infarction(17) and cardiovascular 
mortality(8, 90, 91) observed in obese individuals with the MetS.
Microvascular dysfunction in obesity has also been documented in other vascular beds such 
as the kidney, brain, and skeletal muscle, as noted above. Obesity and MetS augment renal 
vasoconstriction in response to angiotensin II,(92, 93) impair renal autoregulation,(94) and 
blunt myogenic afferent arteriolar constriction.(95) In contrast, diminished vasodilator 
responsiveness and increased myogenic activation is evident in isolated middle cerebral 
arteries and gracilis arterioles from obese Zucker rats.(77, 96, 97) This skeletal muscle 
microvasculopathy is associated with an enhanced rate of fatigue and decreased maximal 
force development of skeletal muscle,(79, 97, 98) which can be largely corrected through 
pharmacologic enhancement of perfusion.(98, 99) Renal, cerebral, and skeletal muscle 
circulations have also been shown to be adversely affected by obesity and the MetS, which 
produce diminish microvascular-capillary density.(9-13, 100, 101) Significant coronary 
vascular remodeling and altered vascular wall mechanics have also been documented in 
obese swine with MetS.(85) Aside from impaired oxygenation and tissue hypoxia, 
microvascular dysfunction in MetS has also been suggested to play a role in the development 
of glomerular injury, tubular atrophy, interstitial fibrosis,(76, 95) and exacerbation of injury 
in the setting of peripheral vascular disease(98) or stroke.(77)
A related aspect of microvascular dysfunction is impaired dilator/constrictor tone. It is 
apparent that underlying activation of the renin-angiotensin-aldosterone system, the 
sympathetic nervous system, and inflammatory pathways contributes to a diminished 
vasodilator and augmented vasoconstrictor phenotype of the MetS.(7) A hallmark of MetS-
induced vascular disease is impaired endothelial function, which is associated not only with 
diminished bioavailability of nitric oxide but also increased production and/or vascular 
sensitivity to endothelial-dependent vasoconstrictors such as endothelin-1, prostaglandin H2, 
and thromboxane A2.(7, 20, 31) Endothelial dysfunction is pathologically important not only 
for the modulation of vascular resistance and tissue perfusion but also as a critical step in the 
initiation and progression of vascular atherogenesis.(102) MetS is also associated with 
alterations in the functional expression of, and electromechanical coupling between, voltage-
dependent K+ and Ca2+ channels.(7, 83, 84, 88, 103, 104) Continued research to elucidate 
the precise mechanisms responsible for the deleterious impact of the MetS on microvascular 
function is needed, and stands to provide novel targets for directed therapies needed to treat 
the pathologic consequences of this multifactorial syndrome.
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MYOCARDIAL METABOLISM IN OBESITY AND THE METABOLIC 
SYNDROME
As noted in the introduction, insulin resistance is a key underlying component of the 
pathophysiology of the MetS. This applies to the heart, which is subject to systemic 
alterations in fuel delivery as well as to the effects of systemically and locally produced 
regulatory factors such as hormones and adipokines. Here we review what is known about 
the dysregulation of myocardial metabolism in obesity/MetS and how this contributes to 
functional abnormalities that characterize this syndrome.
The myocardium is a metabolic omnivore. In other words, myocardium is capable of 
sustained function using fuels including, but not limited to, acetate, glucose or long-chain 
fatty acids. In health the heart preferentially consumes fatty acids, which provides the most 
energy per unit of fuel (i.e. moles of ATP per mole of fatty acid), but conversely requires 
more oxygen for each ATP unit generated (requiring 0.24 mole O2 per mole ATP generated) 
compared to glucose (0.16 mole O2 per mole ATP generated).(105) Like other tissues, the 
myocardium responds to insulin by shifting toward glucose uptake and glucose oxidation,
(106) and interestingly the myocardium also responds to glucagon-like peptide 1 (GLP-1) to 
shift toward glucose uptake and oxidation.(52, 107, 108) Although the capacity of 
myocardial tissues to respond in this way is established, it is not clear how these actions 
contribute to the regulation of myocardial fuel selection in the course of normal physiology.
Abnormalities in myocardial fuel substrate selection in obesity have been described, as well 
as abnormalities in the responses to shifts in substrate availability, and abnormalities in the 
responses to hormonal controls. In obesity, the myocardium exhibits abnormally increased 
rates of fatty acid uptake and oxidation, and an impaired ability to shift away from this 
increased fatty acid utilization.(109, 110) Such abnormalities have been shown in animal 
models of insulin resistance,(111-113) in humans with obesity/insulin resistance,(46, 114, 
115) and in obese humans with Type 2 diabetes.(116) This lipotoxicity effect is in addition 
to the previously described adverse effects of hyperglycemia on myocardial fuel selection 
(which combined exert ‘glucolipotoxicity’) (117), although the hyperglycemia is modest in 
MetS in the absence of concurrent diabetes. Notably, emerging data suggests a sexual 
dimorphism, with increased rates of fatty acid uptake and utilization in female animal 
models(110, 118) and in women.(115, 119, 120) The implications of this sexual difference 
in fuel selection on obesity-related myocardial disease are not yet known, but this 
phenomenon may help explain the relatively greater adverse effect of the development of 
diabetes on myocardial outcomes in women.(114)
Increased fatty acid uptake is not due simply to increased rates of fatty acid delivery in the 
setting of obesity. Rather, there is evidence for increased transport capacity and increased 
rates of fatty acid transport. The major sarcolemmal fatty acid transport proteins, CD36 and 
FATP, are over-expressed in animal models of obesity.(112, 121, 122) Lipoprotein lipase, 
functioning in adipocytes or in vasculature more proximal to the myocardium to liberate 
fatty acids from the circulating storage form of triacyglyerols, may also contribute to the 
detrimental phenotype of elevated fatty acid uptake.(123) Augmented fatty acid uptake in 
obesity is also not simply a neutral shift in fuel preference. Experimental studies limiting or 
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augmenting fatty acid uptake have demonstrated that increased fatty acid uptake can lead to 
impairments in myocardial function, and that limiting fatty acid uptake can rescue the heart 
from this lipotoxic circumstance.(46, 124-128)
Distinct from questions of fatty acid availability and uptake, there is a question of whether 
insulin resistance contributes separately to abnormal myocardial metabolism in obesity. 
Many prior reports have linked obesity and insulin resistance with increased myocardial 
fatty acid uptake and utilization, as detailed above. Resistance to insulin action in the heart 
to drive glucose uptake is not consistently seen, particularly in human studies.(46, 129-132) 
Experimental evidence from animal models demonstrates impairment in insulin-stimulated 
myocardial glucose uptake, impairment in insulin’s effects to modulate blood flow, and 
impairment in insulin’s role as a regulator of cell growth and cell cycle in the setting of 
obesity or isolated myocardial fat loading.(127, 131, 133-135) Nevertheless, from the 
systemic viewpoint it appears that the actions of insulin in tissues outside the heart, acting to 
regulate fuel supply and other regulatory factors, exert larger effects on myocardial 
metabolism than its direct actions on the heart.(106, 129) It is therefore unclear whether 
myocardium-specific insulin resistance is a therapeutic target. Nevertheless, treatments that 
improve systemic insulin resistance can exert beneficial effects on myocardial metabolism, 
so systemic insulin resistance remains a valid overall target.(136-138)
Other features of obesity, such as abnormalities in adipokines (e.g. adiponectin and leptin) 
and increased systemic inflammation, may impact myocardial fuel selection or myocardial 
responses to injury.(139-141) Effects of adiponectin to directly modulate myocardial 
metabolism have been shown in experimental models,(142) and the importance of leptin for 
normal cardiac function and development is demonstrated by the abnormal cardiac 
phenotype of leptin-deficient animals.(143) The actions of these and other adipose-derived 
factors on the heart may reflect concurrent effects on systemic hemodynamics, vascular 
function, endothelial response to injury in addition any direct effects on myocardial 
metabolism.(27, 142, 144)
The implications of these metabolic abnormalities along with microvascular dysfunction and 
atherosclerotic vascular lesions on cardiovascular outcomes in obesity and the MetS are 
discussed separately below.
ATHEROSCLEROTIC DISEASE AND VASCULAR CALCIFICATION
Thirty years of focused research have shown that increasing degrees of obesity and the MetS 
are associated with accelerated atherosclerosis and a greater incidence of coronary heart 
disease.(145-150) These higher rates of atherosclerotic disease have been shown to result in 
an ~2-fold increase in risk of myocardial infarction(17) and a significantly elevated risk of 
cardiovascular mortality.(8, 90, 91) Further, this increase in cardiovascular risk is 
proportionally greater in women compared to men.(10, 17, 90) Recent findings from the 
PROSPECT (Providing Regional Observations to Study Predictors of Events in the 
Coronary Tree) study indicate compositional differences in coronary plaques underlie these 
increased event rates, with evidence for increased prevalence of adverse features (total 
plaque burden, necrotic core and calcium content, among others) in untreated, non-culprit 
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lesions from patients with MetS or diabetes.(151) Increased prevalence and absolute 
progression of coronary artery calcification has also been demonstrated in the setting of the 
MetS and augmented cardiometabolic risk.(152-154)
The molecular mechanisms underlying the augmented initiation and progression of MetS-
induced vascular disease remain an area of active research. Recent work has focused on the 
idea of adipose-derived hormones and cytokines (‘adipokines’) as molecular links between 
adiposity and vascular disease(155). Roles of adipokines in the regulation of many relevant 
features of obesity-associated cardiovascular disease have been described, including effects 
of adipokines on insulin sensitivity (leptin, adiponectin and resistin), inflammation (IL-8, 
monocyte chemotactic protein 1, leptin, chemerin), coagulation (plasminogen activator 
inhibitor-1), and vascular function and atherosclerosis (leptin, resistin, tumor necrosis factor-
alpha, adiponectin,visfatin, omentin).(24, 156-163) Relevant fat depots also include the fat 
on the heart itself. Cardiac adipose tissue volume expands with obesity, but accumulates 
preferentially around coronary arteries, and atherosclerotic plaques occur predominantly in 
arteries encased by perivascular adipose tissue (PVAT).(164, 165 ) Recent work is evaluating 
an “outside-to-inside” signaling paradigm by which adipokines released from coronary 
perivascular adipose tissue (PVAT) are capable of influencing the development of vascular 
dysfunction and atherosclerosis in immediately adjacent vessels.(156, 166-170) Future 
studies are needed to better delineate the relative importance of systemically derived versus 
locally produced adipokines, to better understand the molecular mechanisms linking 
adipokines to vascular pathophysiology, and to assess whether these signaling pathways 
constitute therapeutic targets that may be of specific benefit in combating cardiovascular 
disease in obesity and MetS.
MYOCARDIAL INFARCTION AND HEART FAILURE IN OBESITY AND THE 
METABOLIC SYNDROME
Obesity and the MetS are associated with increased risk of heart disease, with two distinct 
diseases represented. First, obesity predisposes to congestive heart failure. Second, obesity is 
a contributor to risk of atherosclerotic heart disease, distinct from the effects of concurrent 
diabetes. The other components of the MetS are themselves epidemiologic risk factors for 
these conditions, working concurrent with the obesity effect to augment risk for each of 
these conditions.
The association of obesity with congestive heart failure is well recognized but remains 
unexplained. This condition was historically called ‘obesity cardiomyopathy’, and felt to 
arise due to effects of systemic and pulmonary hypertension, with contributory effects of 
obstructive sleep apnea.(20, 171) Unlike heart failure associated with atherosclerotic disease, 
diastolic dysfunction is a dominant aspect of the obesity-associated impairment in 
myocardial function.(172) Experimental and clinical trial evidence suggests that some of this 
dysfunction is associated with the aberrant fatty acid uptake phenotype of the obese heart, 
and amenable to improvement by reducing myocardial fatty acid uptake.(173-176) 
Epidemiologic evidence links hyperinsulinemia with heart failure,(177-179) and there is a 
body of experimental study evidence suggesting that insulin resistance in the heart is a 
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contributor to the pathogenesis of heart failure.(129, 131) Unfortunately this literature is 
confusing in that insulin resistance is also described as a consequence of heart failure of 
various etiologies, with opposite systemic metabolic phenotypes to what is seen in obesity.
(180-182) Emerging evidence suggests that impaired myocardial metabolic responses to 
GLP-1 may exist in obesity.(62, 183) GLP-1 derived treatments may represent a novel 
approach to metabolic modulation for heart failure,(184, 185) although the myocardial 
effects in populations with obesity will need to be carefully evaluated.
The association of obesity with atherosclerotic heart disease has been recognized for more 
than 50 years.(147) The ongoing obesity epidemic has made this component of population 
cardiovascular disease risk increasingly apparent, and urgent. The approach to 
cardiovascular disease prevention and management is not different in those with obesity, and 
is focused on prevention through management of risk factors such as blood pressure, 
smoking, and cholesterol (primarily with ‘statin’ class medications) and on revascularization 
when necessary. Weight loss interventions, including diet/exercise (‘lifestyle’) paradigms, 
pharmacologic treatment and surgically induced weight loss, can reverse the magnitude of 
cardiovascular risk that is represented in the MetS components (186-189). However, lifestyle 
change to induce weight loss failed to improve cardiovascular risk among a population with 
type 2 diabetes in the LookAHEAD study.(186) Similarly, medications that induce weight 
loss have not been shown to prevent future cardiovascular disease, and in some instances 
these medications also exert separate adverse cardiac effects.(187, 188) In contrast, 
surgically-induced weight loss studies suggest long-term survival benefits including diabetes 
remission and reduced rates of atherosclerotic coronary vascular disease, (186, 190, 191), 
along with improvements in obesity-associated derangements in cardiac microcirculation, 
structure, and function (192, 193). These discordant results suggest that either the degree of 
weight loss with non-surgical approaches was insufficient to achieve benefit, or that 
surgically induced weight loss confers weight-independent cardioprotection. Therapies 
targeting metabolic abnormalities for atherosclerotic heart disease in obesity are under 
investigation. Prior studies were focused on potential benefits of PPAR-gamma agonists 
(modulating fatty acid delivery and peripheral insulin resistance),(194) but this class of 
agents has since fallen out of favor with subsequent revelations of increased fluid retention 
rates, increased rates of bone loss, and uncertainty regarding net cardiovascular disease 
benefits. More recently the glucagon-like peptide 1 (GLP-1) mimetics have begun to be 
evaluated. These treatments, originally developed for management of glycemia in Type 2 
diabetes, may have distinct beneficial effects to reduce rates of atherosclerotic disease and it 
is likely that studies of cardioprotection in obesity will be soon to follow.(183, 195-197)
INSIGHTS FROM PROTEOMIC AND GENOMIC STUDIES
As with the physiologic changes seen in obesity/MetS, the genetic and molecular factors 
underlying the cardiovascular perturbations in MetS are complex and inter-related. A 
considerable body of evidence has been produced identifying molecular changes associated 
with obesity and the individual components of the MetS. Modern high-throughput, 
comprehensive molecular methodologies (the so-called ‘omics’ methods) assessing genetics, 
nucleic acids, proteins, or metabolites hold the promise of providing insights into biologic 
processes with an opportunity to assess all concurrent molecular changes. These methods 
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can provide powerful integrative insights into whole-body, tissue, and/or cellular physiology, 
but at the cost of producing a large number of inter-related results that can be challenging to 
interpret. Associations between select miR species and specific cardiovascular disease, along 
with associations with putative mechanistic mediators, have been observed for atrial 
fibrillation (198), and cerebrovascular disease (199), along with associations with 
pathophysiologic mediators of vascular disease including lipid metabolism (200)and 
endothelial dysfunction (201). A comprehensive review of the current state of knowledge 
linking miR and cardiovascular disease has recently been published (202). The literature 
specifically evaluating miR associations with cardiovascular disease in obesity/MetS is 
relatively sparse, and in the current context worthy of a detailed presentation.
Using microarrays, Phillip-Couderc et al. identified 63 genes that were differentially 
expressed in dog ventricles following 24 weeks of diet-induced obesity and hypertension.
(203) Using hierarchical clustering analyses, they were able to identify groups of co-
regulated genes and ascribe predicted functions to the products of the differentially 
expressed genes. The identified gene groupings were associated with many diverse cellular 
functions in the myocardium including regulation of cell proliferation and cell structure, key 
functional pathways such as calcium handling, response to cellular stress, and regulation of 
energy metabolism and mitochondrial function.(203) Of note, this study demonstrated that 
changes to the transcriptome took place continuously over the 24 week experimental 
timeline.
Nucleic acids are now well recognized to fill roles beyond information storage and 
transmission. Multiple functional RNA moieties have been discovered, including subsets 
with particular topological structures (e.g. shRNA), and others with sequence-specific 
actions to modulate transcription (siRNA) or post-transcriptional events (lncRNA, miRNA). 
One important group of post-transcriptional modulators, the microRNAs (miR), have been 
reported to contribute to the regulation of metabolic disease(204-206) and of cardiovascular 
disease.(207-209) Initial studies of the effects of miRs were associative and often focused on 
single miR species, but studies of the regulation of miRs, direct actions of miRs, and 
concurrent changes in multiple miR species are beginning to appear. For example, recent 
work by our lab(52) and others(204, 210) suggests that a complex system of factors (obesity/
MetS, myocardial ischemia, pharmacologic therapy) alters the expression of miRs which in 
turn are linked with the regulation of cellular functions and/or pathophysiologic responses. 
The emerging paradigm is one in which miR expression changes are not necessarily 
inextricably related to a particular pathology (though some may be(210)), but instead are 
determined by multiple concurrent factors including underlying metabolic disease, 
cardiovascular pathology (e.g. atherosclerotic disease, ischemic heart disease, heart failure) 
and exposure to pharmacotherapy. For example a randomized, placebo-controlled, double-
blinded study with 18 placebo and 17 metformin treated patients with type 2 diabetes 
mellitus found that metformin-specific changes in insulin resistance were associated with 
differential changes in circulating levels of miR-140-5p, miR-222, miR-142, and miR-192.
(204) Work from our laboratory in Ossabaw swine assessed left ventricular miR expression 
changes in response to combinations of stimuli including diet-induced obesity, myocardial 
ischemia, and exendin-4, a GLP-1 mimetic.(52) We found that miR expression was 
regulated in complex ways, where some miR changes were related to the obese condition 
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(e.g. miR133a-5p), while others were specific to the exendin treatment (e.g. miR15, miR 
let7).(52) These observations are associative; how these miRs are related to the physiologic 
effects or treatment responses is unknown at present. These observations highlight both the 
strengths and the challenges of exploring physiology using high-throughput measures.
As with other high-throughput integrative testing approaches, proteomic approaches promise 
to advance our understanding of physiology and pathophysiology. Many forms of protein 
mass-spectrometry allow for antibody-independent, label-free quantification and analysis of 
protein components within a tissue. Whole proteome analyses have previously been utilized 
to demonstrate obesity-specific changes in abundance and phosphorylation of proteins 
related to ion transport, mitochondrial metabolism, antioxidant function and cardiac 
contractile function.(211-215) Some work has been done exploring the proteomic responses 
to ischemia in non-obese models,(216-219) but very little work has been done to date 
exploring obesity-specific proteomic changes associated with myocardial ischemia or in 
relation to obesity-specific cardiac dysfunction. Our own work presents an initial foray into 
these questions.(52) In our studies in Ossabaw swine, the proteomic changes associated with 
obesity, ischemia and exendin-4 treatment provided intriguing novel observations of obesity-
related changes in the structural protein titin and in multiple components of the myocelluar 
calcium-regulating machinery.(52) These results need confirmation and further exploration, 
but along with the miR observations underscore the value of these ‘omic’ approaches as 
tools for discovery.
SUMMARY AND FUTURE DIRECTIONS
The MetS is defined as the concurrence of mutually associated cardiovascular risk factors 
including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, decreased 
HDL cholesterol, and/or hypertension. In association with these factors, many investigators 
have described the activation of the sympathetic nervous system, renin-angiotensin system, 
and increased levels of pro-inflammatory adipokines and cytokines which subsequently 
contribute to increases in heart rate, circulating blood volume, ventricular end-diastolic 
volume, cardiac output, and vascular resistance. This hemodynamic phenotype is associated 
with cardiovascular disease risk. The associated pathophysiologic changes include 
alterations in myocardial substrate metabolism, microvascular dysfunction, impaired oxygen 
supply/demand balance, cardiac (diastolic) contractile dysfunction, and concentric cardiac 
hypertrophy (summarized in the Figure). These changes are distinct from the 
pathophysiology in conduit vessels through the processes of traditional atherosclerosis and 
arterial calcification, which are also augmented and contribute to adverse cardiovascular 
outcomes. (17) Despite significant advances made to date, the physiological and molecular 
mechanisms of metabolic, functional and vascular disease in obesity/MetS remain poorly 
understood. The most obvious hurdle is the complicated, inter-dependent multi-factorial 
nature of the syndrome itself, making it difficult to disentangle relevant factors or specific 
combinations of factors. It is also possible that the most relevant features are separate from 
the defining cardiovascular disease risk factors and have yet to be identified. Adipokines 
have been suggested as one possible example of such integrative underlying factors, but the 
potential also exists for ‘omic’ approaches to provide insight into molecules and 
mechanisms of which we are not yet even aware. There is a clear need for ongoing 
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exploration of these issues, to better understand and better treat obesity and MetS-associated 
cardiovascular disease, in order to better address the considerable public health implications 
of these conditions.
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Figure. 
Schematic diagram of the pathologic features, adverse molecular and systemic changes, and 
cardiovascular consequences of the metabolic syndrome. Clustering of causally inter-related 
risk factors including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, 
decreased HDL cholesterol, and/or hypertension is associated activation of the sympathetic 
nervous system, renin-angiotensin-aldosterone system (RAAS), and increased levels of pro-
inflammatory adipokines and cytokines. These phenotypic changes subsequently contribute 
to increases in heart rate, circulating blood volume, cardiac output, vascular resistance, and 
changes in myocardial metabolism. The consequences of these changes include 
microvascular dysfunction, cardiac contractile dysfunction (augmented end-diastolic volume 
and systemic pressure development observed in left ventricular pressure-volume relationship 
(data from Sassoon et al.(52)), atherosclerotic disease (L = lumen; M = media; image of 
human coronary artery from Noblet et al.(170)), vascular calcification (arrow points to 
calcification; image provided by Dr. Michael Sturek with permission), concentric cardiac 
hypertrophy, myocardial infarction, and heart failure.
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